for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chromadex Corp

CDXC.OQ

Latest Trade

4.08USD

Change

-0.07(-1.69%)

Volume

156,867

Today's Range

4.00

 - 

4.22

52 Week Range

2.79

 - 

4.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.15
Open
4.14
Volume
156,867
3M AVG Volume
5.46
Today's High
4.22
Today's Low
4.00
52 Week High
4.95
52 Week Low
2.79
Shares Out (MIL)
55.72
Market Cap (MIL)
227.33
Forward P/E
-7.85
Dividend (Yield %)
--

Latest Developments

More

Chromadex Q2 Loss Per Share $0.14

Pioneer Step Holdings Limited Reports 9.6 Percent Stake In Chromadex As Of May 9

Chromadex Q1 Loss Per Share $0.15

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chromadex Corp

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Industry

Biotechnology & Drugs

Contact Info

10900 Wilshire Blvd Ste 650

+1.310.3886706

https://chromadex.com/default.aspx

Executive Leadership

Frank L. Jaksch

Executive Chairman of the Board

Robert N. Fried

President, Chief Executive Officer, Chief Operating Officer, Chief Strategy Officer, Director

Kevin M. Farr

Chief Financial Officer

Matthew A. Roberts

Senior Vice President - Innovation, Chief Scientific Officer

Lisa Bratkovich

Chief Marketing Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.030

2017

-0.260

2018

-0.610

2019(E)

-0.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.93
Price To Book (MRQ)
14.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
68.74
LT Debt To Equity (MRQ)
0.80
Return on Investment (TTM)
-106.97
Return on Equity (TTM)
-68.07

Latest News

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage:

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016 Source text: (http://bit.ly/2zpFLpg) Further company coverage:

BRIEF-ChromaDex Q3 loss per share $0.07 from continuing operations

* Q3 sales rose 55 percent to $6.1 million Source text for Eikon: Further company coverage:

BRIEF-Chromadex announces $23 mln private placement of common stock

* Chromadex announces $23 million private placement of common stock

BRIEF-Chromadex Corp files for common stock offering by selling stockholders of up to $7.7 mln

* Chromadex Corp files for common stock offering by selling stockholders of up to $7.7 million - SEC filing Source text: [http://bit.ly/2z2cq3P] Further company coverage:

BRIEF-Chromadex announces top-line results of its second human clinical trial

* Chromadex announces top-line results of its second human clinical trial

BRIEF-ChromaDex Partners with Watsons, for TRU NIAGEN retail launch

* ChromaDex Corp - new partnership with Hong Kong based retailer, A.S. Watson, for launch of U.S. Made TRU NIAGEN) dietary supplement in Asia Source text for Eikon: Further company coverage:

BRIEF-Chromadex's units enter asset purchase agreement with Covance Laboratories Inc​

* Chromadex Corp - on august 21, 2017, co's units entered into an asset purchase agreement with Covance Laboratories Inc

BRIEF-Chromadex sells its analytical testing business to LabCorp

* Chromadex sells its analytical testing business to LabCorp, to accelerate the expansion of Nicotinamide Riboside and its other patented ingredient technologies

BRIEF-Chromadex announces closing of final tranche of $25 mln strategic investment and appoints two new board members

* Chromadex announces closing of third and final tranche of the $25 million strategic investment led by Mr. Li Ka-shing and appoints two additional board members

BRIEF-ChromaDex Q2 loss per share $0.07

* Q2 loss per share $0.07 Source text for Eikon: Further company coverage:

BRIEF-Chromadex announces worldwide patent license and research agreement with the Scripps Research Institute

* Chromadex announces an exclusive worldwide patent license and research agreement with the Scripps Research Institute to identify the potential role of Niagen in treating breast cancer

BRIEF-Chromadex says files for resale of up to 7.65 mln shares by selling stockholders

* Chromadex Corp files for resale from time to time of up to 7.65 million shares of co's common stock by the selling stockholders - SEC filing Source text - http://bit.ly/2rK2K9T Further company coverage:

BRIEF-Chromadex Q1 loss per share $0.05

* Q1 sales fell 39 percent to $4.4 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up